COSM Cosmos Health Inc.
Price Chart
Executive Summary
Cosmos Health's subsidiary Cana Laboratories acquired international patent application WO2025108566A1 from Cloudpharm P.C. and plans expanded nanotechnology investments. The deal adds early-stage IP to Cosmos's portfolio but lacks disclosed financial terms, FDA catalyst, or near-term revenue impact — making it an early-stage R&D step with limited immediate valuation effect.
Actionable Insight
Monitor Cosmos for the next quarterly filing (10-Q) detailing R&D expense associated with the nanotechnology initiative and any patent-office updates. Without disclosed deal economics or revenue guidance, this filing does not alter near-term financial projections.
Key Facts
- Cana Laboratories acquired patent application WO2025108566A1 from Cloudpharm P.C.
- Patent protection being pursued at national/regional levels across key international markets.
- Technology targets pharma, nutraceutical, OTC, and specialized healthcare products.
- Cana Laboratories is European GMP-licensed and EMA-certified.
- No financial terms (deal value, upfront, milestones) disclosed.
- No revenue contribution or commercial launch timeline provided.
Financial Impact
Undisclosed — no consideration, milestones, or revenue projections provided in the release.
Risk Factors
- Patents remain at application stage — no guarantee of grant or commercial viability.
- No disclosed cash outflow or financing commitment could create future dilution if R&D spend escalates.
- Micro-cap liquidity ($15M market cap) amplifies downside if IP fails to monetize.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 17, 2026
3d ago
|
Press Release
| $0.2417 $0.2129 | ▼ −11.92% | ▼ −12.70% | $0.2130 (−11.87%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 12, 2026
8d ago
|
Press Release
| $0.2100 $0.2371 | ▲ +12.90% | ▲ +11.14% | $0.2130 (+1.43%) |
|
Jun 10, 2026
10d ago
|
Press Release
| $0.2281 $0.2060 | ▼ −9.69% | ▼ −11.39% | $0.2130 (−6.62%) |
|
Jun 9, 2026
11d ago
|
Press Release
| $0.2233 $0.2281 | ▲ +2.15% | ▲ +3.73% | $0.2130 (−4.61%) |
|
Jun 8, 2026
12d ago
|
Press Release
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 6, 2026
15d ago
|
S-3/A
| $0.2300 $0.2233 | ▲ +2.91% | ▲ +2.62% | $0.2130 (+7.39%) |
|
Jun 5, 2026
15d ago
|
DEFA14A
| $0.2300 $0.2233 | ▼ −2.91% | ▼ −2.62% | $0.2130 (−7.39%) |
|
Jun 1, 2026
19d ago
|
Press Release
| $0.2530 $0.2610 | ▲ +3.16% | ▲ +3.02% | $0.2130 (−15.81%) |
|
May 26, 2026
25d ago
|
Press Release
| $0.2630 $0.2650 | ▲ +0.76% | ▲ +0.75% | $0.2130 (−19.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access